Feb 18, 2026
Tavapadon is a new investigational medication for Parkinson’s disease that works very differently from traditional dopamine agonists. Instead of broadly stimulating dopamine receptors, tavapadon selectively targets D1 receptors—the brain’s primary “go” signal for movement—and does so as a partial agonist.
In...
Feb 4, 2026
In this episode (watch on YouTube) we examine recent lab and animal research suggesting ivermectin — a widely used antiparasitic — can alter striatal circuits and enhance L-DOPA responses in preclinical Parkinson’s models.
We’ll explain the likely mechanisms (ion-channel modulation at P2X4 and nicotinic...